## Wayne A Phillips

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6205441/publications.pdf

Version: 2024-02-01

		61984	6	2596
131	7,115	43		80
papers	citations	h-index		g-index
139	139	139		12308
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. Oncogene, 2022, 41, 3445-3451.	5.9	2
2	Elevation of fatty acid desaturaseÂ2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acidâ€induced DNA damage. Clinical and Translational Medicine, 2022, 12, e810.	4.0	6
3	Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. Cell Death and Differentiation, 2022, 29, 2288-2302.	11.2	6
4	Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 689-713.	4.5	11
5	Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation. Scientific Reports, 2021, 11, 4480.	3 <b>.</b> 3	5
6	HOXA13 in etiology and oncogenic potential of Barrett's esophagus. Nature Communications, 2021, 12, 3354.	12.8	5
7	SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than <i>TP53</i> Mutation Status. Molecular Cancer Therapeutics, 2021, 20, 1858-1867.	4.1	24
8	Trapping Colorectal Cancer Into a Dead-end. Gastroenterology, 2021, 161, 33-35.	1.3	0
9	732 TUMOR INFILTRATING NEUTROPHILS ARE A POOR PROGNOSTIC MARKER FOR ESOPHAGEAL CANCER PATIENTS RECEIVING NEOADJUVANT CHEMORADIOTHERAPY. Ecological Management and Restoration, 2021, 34, .	0.4	O
10	Molecular and genomic characterisation of a panel of human anal cancer cell lines. Cell Death and Disease, 2021, 12, 959.	6.3	3
11	Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression. Molecular Cell, 2020, 80, 279-295.e8.	9.7	14
12	<scp>GRB7</scp> is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma. Journal of Pathology, 2020, 252, 317-329.	<b>4.</b> 5	8
13	Clinical pathways and outcomes of patients with Barrett's esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008–2016. Ecological Management and Restoration, 2020, 34, .	0.4	O
14	Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations. Biomolecules, 2019, 9, 158.	4.0	13
15	MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer. Journal of Nuclear Medicine, 2019, 60, 917-923.	5.0	7
16	Evaluating and manipulating the immune landscape in hepatic verses peritoneal metastases arising from colorectal primary tumors Journal of Clinical Oncology, 2019, 37, 568-568.	1.6	0
17	Abstract 4618: A novelPik3ca-driven mouse model and syngeneic cancer cell line for the preclinical testing of targeted and immune therapies for anal squamous cell carcinoma (ASCC)., 2019,,.		О
18	Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and metaâ€analysis. Colorectal Disease, 2018, 20, 574-585.	1.4	47

#	Article	IF	Citations
19	Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. Diseases of the Colon and Rectum, 2018, 61, 179-186.	1.3	18
20	PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein. Neuro-Oncology, 2018, 20, 1344-1355.	1.2	23
21	Identification of <i>Pik3ca</i> Mutation as a Genetic Driver of Prostate Cancer That Cooperates with <i>Pten</i> Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discovery, 2018, 8, 764-779.	9.4	72
22	Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. JCO Precision Oncology, 2018, 2, 1-15.	3.0	46
23	Preclinical models for the study of Barrett's carcinogenesis. Annals of the New York Academy of Sciences, 2018, 1434, 139-148.	3 <b>.</b> 8	3
24	Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing. Annals of Surgical Oncology, 2018, 25, 2731-2738.	1.5	18
25	<i>TP53</i> is not a prognostic markerâ€"clinical consequences of a generally disregarded fact. Annals of the New York Academy of Sciences, 2018, 1434, 46-53.	3.8	2
26	Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus. Molecular and Cellular Proteomics, 2018, 17, 2324-2334.	3.8	25
27	Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. British Journal of Surgery, 2017, 104, 990-1002.	0.3	84
28	Inhibiting the system xCâ^'/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications, 2017, 8, 14844.	12.8	229
29	Combined CDK4/6 and Pl3K $\hat{l}_{\pm}$ Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 6340-6352.	0.9	163
30	Inhibiting system x <sub>C</sub> <sup>â^'</sup> and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers. Molecular and Cellular Oncology, 2017, 4, e1344757.	0.7	12
31	Remodeling Barrett's Metaplasia in a Novel in vivo Organoid Model. Gastroenterology, 2017, 152, S125.	1.3	O
32	Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nature Communications, 2017, 8, 1773.	12.8	54
33	Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 24604-24620.	1.8	24
34	PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. Oncotarget, 2017, 8, 103207-103222.	1.8	18
35	Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget, 2016, 7, 37064-37080.	1.8	69
36	Somatic activating mutations in <i>Pik3ca</i> cause sporadic venous malformations in mice and humans. Science Translational Medicine, 2016, 8, 332ra43.	12.4	138

#	Article	IF	CITATIONS
37	The Genetics of Barrett's Esophagus: A Familial and Population-Based Perspective. Digestive Diseases and Sciences, 2016, 61, 1826-1834.	2.3	7
38	Sa1798 Expression of Bone Morphogenic Protein 4 (BMP4) in Esophageal Cancer is Regulated by Stroma-Dependent Sonic Hedgehog Signals. Gastroenterology, 2016, 150, S369.	1.3	0
39	136 A Novel Xenograft Model of Human Barrett's Esophagus. Gastroenterology, 2016, 150, S33.	1.3	0
40	Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Disease, 2016, 18, 234-246.	1.4	122
41	Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts. Annals of Surgical Oncology, 2016, 23, 305-311.	1.5	23
42	Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis, 2016, 37, 356-365.	2.8	46
43	Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis. Oncotarget, 2016, 7, 83342-83358.	1.8	14
44	Abstract 4357: Harnessing system xCT- to target mutant p53 cancer cells. , 2016, , .		0
45	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut, 2015, 64, 1506-1516.	12.1	84
46	Ubiquitous expression of the <i>Pik3ca <sup>H1047R</sup> </i> mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. FASEB Journal, 2015, 29, 1426-1434.	0.5	24
47	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature, 2015, 525, 119-123.	27.8	284
48	Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncology, The, 2015, 16, e611-e621.	10.7	63
49	Heterozygous expression of the oncogenic Pik3caH1047R mutation during murine development results in fatal embryonic and extraembryonic defects. Developmental Biology, 2015, 404, 14-26.	2.0	32
50	The polarity protein Scrib mediates epidermal development and exerts a tumor suppressive function during skin carcinogenesis. Molecular Cancer, 2015, 14, 169.	19.2	31
51	PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in <i>BRAF</i> Melanoma. Cancer Discovery, 2015, 5, 143-153.	9.4	51
52	Abstract B31: Targeting PI3K and RAS pathways in a novel preclinical model of prostate cancer., 2015,,.		0
53	Abstract IA29: PI3â $\in$ 2 -kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAFV600E/PTENNull melanoma. , 2015, , .		0
54	Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. Oncogenesis, 2014, 3, e108-e108.	4.9	82

#	Article	IF	CITATIONS
55	Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells. Bioscience Reports, 2014, 34, .	2.4	1
56	Physiological expression of the PI3K-activating mutation <i>Pik3ca</i> H1047R combines with <i>Apc</i> loss to promote development of invasive intestinal adenocarcinomas in mice. Biochemical Journal, 2014, 458, 251-258.	3.7	20
57	Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. Molecular Cancer Research, 2014, 12, 979-986.	3.4	92
58	PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Research, 2014, 16, 201.	5.0	94
59	Characterization of a Novel Tumorigenic Esophageal Adenocarcinoma Cell Line: OANC1. Digestive Diseases and Sciences, 2014, 59, 78-88.	2.3	10
60	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nature Communications, 2014, 5, 5224.	12.8	236
61	Abstract 86: Heterozygous expression of an oncogenic Pik3ca mutation during murine development results in fatal embryonic and extra-embryonic defects. , 2014, , .		0
62	Advances in understanding the pathogenesis of Barrett's esophagus. Discovery Medicine, 2014, 17, 7-14.	0.5	12
63	Molecular changes in the phosphatidylinositide 3â€kinase (PI3K) pathway are common in gastric cancer. Journal of Surgical Oncology, 2013, 108, 113-120.	1.7	11
64	Mutationally Activated PIK3CAH1047R Cooperates with BRAFV600E to Promote Lung Cancer Progression. Cancer Research, 2013, 73, 6448-6461.	0.9	40
65	Barrett's esophagus: cancer and molecular biology. Annals of the New York Academy of Sciences, 2013, 1300, 296-314.	3.8	24
66	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. European Journal of Cancer, 2013, 49, 3936-3944.	2.8	72
67	Human perforin mutations and susceptibility to multiple primary cancers. Oncolmmunology, 2013, 2, e24185.	4.6	57
68	Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biology and Therapy, 2013, 14, 782-795.	3.4	40
69	Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. Journal of Clinical Investigation, 2013, 123, 5104-5118.	8.2	72
70	Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. American Journal of Physiology - Renal Physiology, 2012, 303, G1335-G1346.	3.4	50
71	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews in Oncogenesis, 2012, 17, 69-95.	0.4	204
72	A Central Role for RAFâ†'MEKâ†'ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discovery, 2012, 2, 685-693.	9.4	264

#	Article	IF	CITATIONS
73	Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. Hpb, 2012, 14, 333-340.	0.3	14
74	Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity. BMC Biochemistry, 2012, 13, 30.	4.4	9
75	Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer, 2012, 12, 141.	2.6	20
76	The developing clinical problem of chemotherapyâ€induced hepatic injury. ANZ Journal of Surgery, 2012, 82, 23-29.	0.7	15
77	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. Journal of Clinical Investigation, 2012, 122, 553-557.	8.2	174
78	Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors. PLoS ONE, 2012, 7, e36924.	2.5	57
79	Developing a Quantitative In Vivo Tissue Reconstitution Assay to Assess the Relative Potency of Candidate Populations of Mouse Oesophageal Epithelial Cells. Methods in Molecular Biology, 2012, 879, 73-88.	0.9	0
80	Abstract 3289: Tissue specific expression of the PI 3-kinase mutation Pik3caH1047R induces hyperplasia and tumorigenesis in a mouse model., 2012,,.		0
81	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PLoS ONE, 2011, 6, e18064.	2.5	172
82	Barrett's esophagus. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 639-648.	2.8	51
83	mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. Hpb, 2011, 13, 811-816.	0.3	10
84	Using Gene Expression Profiling to Predict Response and Prognosis in Gastrointestinal Cancersâ€"The Promise and the Perils. Annals of Surgical Oncology, 2011, 18, 1484-1491.	1.5	28
85	Pretreatment Transcriptional Profiling for Predicting Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma. Clinical Cancer Research, 2011, 17, 3039-3047.	7.0	50
86	<i>&gt;PIK3CA</i> mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10208-10213.	7.1	324
87	Aberrant Epithelial–Mesenchymal Hedgehog Signaling Characterizes Barrett's Metaplasia. Gastroenterology, 2010, 138, 1810-1822.e2.	1.3	156
88	Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated Bâ€Raf. International Journal of Cancer, 2009, 125, 297-307.	5.1	36
89	Esophageal Stem Cells—A Review of Their Identification and Characterization. Stem Cell Reviews and Reports, 2008, 4, 261-268.	<b>5.</b> 6	37
90	Reconstitution of stratified murine and human oesophageal epithelia in an <i>in vivo</i> transplant culture system. Scandinavian Journal of Gastroenterology, 2008, 43, 1158-1168.	1.5	12

#	Article	IF	Citations
91	Identification of Candidate Murine Esophageal Stem Cells Using a Combination of Cell Kinetic Studies and Cell Surface Markers. Stem Cells, 2007, 25, 313-318.	3.2	86
92	Gene expression profiling of esophageal cancer: Comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. International Journal of Cancer, 2007, 120, 1914-1921.	5.1	86
93	Pretreatment Gene Expression Profiles Can Be Used to Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. Annals of Surgical Oncology, 2007, 14, 3602-3609.	1.5	58
94	ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix. Oncogene, 2006, 25, 3924-3933.	5.9	22
95	Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes and Cancer, 2006, 45, 1143-1154.	2.8	73
96	Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. International Journal of Cancer, 2006, 118, 2644-2646.	5.1	83
97	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. Cancer Research, 2006, 66, 11718-11725.	0.9	85
98	Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers. Clinical Cancer Research, 2006, 12, 3713-3715.	7.0	12
99	Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation, 2005, 73, 142-153.	1.9	52
100	PIK3CA Mutations in Ovarian Cancer. Clinical Cancer Research, 2005, 11, 7042-7043.	7.0	25
101	The Ras/Mitogen-Activated Protein Kinase Pathway Inhibitor and Likely Tumor Suppressor Proteins, Sprouty 1 and Sprouty 2 Are Deregulated in Breast Cancer. Cancer Research, 2004, 64, 6127-6136.	0.9	159
102	Regulation of Phosphoinositide 3-Kinase by Its Intrinsic Serine Kinase Activity In Vivo. Molecular and Cellular Biology, 2004, 24, 966-975.	2.3	60
103	Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene, 2004, 23, 7726-7733.	5.9	200
104	Mutation of the PIK3CA Gene in Ovarian and Breast Cancer. Cancer Research, 2004, 64, 7678-7681.	0.9	864
105	Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer. British Journal of Cancer, 2003, 88, 270-276.	6.4	34
106	Functional Abnormalities in Protein Tyrosine Phosphatase Îμ-Deficient Macrophages. Biochemical and Biophysical Research Communications, 2001, 286, 184-188.	2.1	44
107	Expression of Wnt genes in human colon cancers. Cancer Letters, 2001, 166, 185-191.	7.2	39
108	Expression of interleukin-6, leukemia inhibitory factor and their receptors by colonic epithelium and pericryptal fibroblasts. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 991-1000.	2.8	18

#	Article	IF	CITATIONS
109	Id2 Is a Target of the $\hat{I}^2$ -Catenin/T Cell Factor Pathway in Colon Carcinoma. Journal of Biological Chemistry, 2001, 276, 45113-45119.	3.4	123
110	Short-chain fatty acids reduce expression of specific protein kinase C isoforms in human colonic epithelial cells., 2000, 182, 222-231.		17
111	Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. Cancer Letters, 2000, 150, 57-62.	7.2	17
112	Microsatellite instability in gastrointestinal tract tumours. International Journal of Surgical Investigation, 2000, 2, 267-74.	0.0	6
113	Activation of protein kinase C augments butyrate-induced differentiation and turnover in human colonic epithelial cells in vitro. Carcinogenesis, 1999, 20, 977-984.	2.8	26
114	Lipopolysaccharide-induced priming of the human neutrophil is not associated with a change in phosphotyrosine phosphatase activity. International Journal of Biochemistry and Cell Biology, 1999, 31, 585-593.	2.8	8
115	Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors., 1998, 83, 41-47.		81
116	Phosphotyrosine phosphatase activity in the macrophage is enhanced by lipopolysaccharide, tumor necrosis factor α, and granulocyte/macrophage-colony stimulating factor: correlation with priming of the respiratory burst. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1355, 343-352.	4.1	7
117	Direct PCR from Paraffin-Embedded Tissue. BioTechniques, 1997, 22, 638-640.	1.8	20
118	FREQUENCY AND CLINICO-PATHOLOGICAL ASSOCIATIONS OF RAS MUTATIONS IN COLORECTAL CANCER IN THE VICTORIAN POPULATION. ANZ Journal of Surgery, 1997, 67, 233-238.	0.7	6
119	Role of YopH in the suppression of tyrosine phosphorylation and respiratory burst activity in murine macrophages infected with <i>Yersinia enterocolitica</i> Journal of Leukocyte Biology, 1995, 57, 972-977.	3.3	45
120	Single-step direct PCR amplification from solid tissues. Nucleic Acids Research, 1995, 23, 1640-1640.	14.5	13
121	Activation of the macrophage respiratory burst by phorbol myristate acetate: Evidence for both tyrosine-kinase-dependent and -independent pathways. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1222, 241-248.	4.1	28
122	Haematopoietic Colony Stimulating Factors CSF-1 and GM-CSF Increase Phosphatidylinositol 3-Kinase Activity in Murine Bone Marrow-Derived Macrophages. Growth Factors, 1994, 10, 181-192.	1.7	18
123	Expression of p47- <i>phox</i> and p67- <i>phox</i> proteins in murine bone marrow–derived macrophages: Enhancement by lipopolysaccharide and tumor necrosis factor <i>α</i> but not colony stimulating factor 1. Journal of Leukocyte Biology, 1994, 55, 530-535.	3.3	27
124	The effect of interleukin-4 on the macrophage respiratory burst is species dependent. Biochemical and Biophysical Research Communications, 1992, 182, 727-732.	2.1	12
125	Protein kinase C has both stimulatory and suppressive effects on macrophage superoxide production. Journal of Cellular Physiology, 1992, 152, 64-70.	4.1	10
126	Colony stimulating factor-1 Is a negative regulator of the macrophage respiratory burst. Journal of Cellular Physiology, 1990, 144, 190-196.	4.1	18

#	Article	IF	CITATION
127	Activation and proliferation signals in murine macrophages: Relationships among c-fos and c-myc expression, phosphoinositide hydrolysis, superoxide formation, and DNA synthesis. Journal of Cellular Physiology, 1989, 141, 618-626.	4.1	36
128	Intracellular plateletâ€activating factor regulates eicosanoid generation in guineaâ€pig resident peritoneal macrophages. British Journal of Pharmacology, 1989, 98, 141-148.	5.4	48
129	Changes in the Incorporation of Free Fatty Acids Upon the Stimulation of Human Polymorphonuclear Leukocytes. Journal of Leukocyte Biology, 1986, 39, 267-284.	3.3	23
130	Recurrent and persistent infections in related Weimaraner dogs. Australian Veterinary Journal, 1984, 61, 261-263.	1.1	21
131	Separation and detection of nitroblue tetrazolium-reducing enzymes from human polymorphonuclear leukocytes. Journal of Immunological Methods, 1982, 54, 175-181.	1.4	1